Webinar: How advances in rapid point-of-care technologies are enabling ultra-high sensitivity detection of biomarkers

In this presentation, Lumos Diagnostics and nanoComposix explore technological advances in next generation nanoparticles, assay chemistries, and reader devices to improve the performance of rapid point-of-care (POC) tests.

View Now


The cardiac biomarker, Troponin has been used as a model assay to demonstrate how the sensitivity of lateral flow tests can be extended towards the limits of antibody affinity. The presentation will describe how the combination of the latest assay and reader developments can push the boundaries of sensitivity and quantification and challenge preconceived limitations of rapid POC testing.

May 30, 2019

Lumos Diagnostics and RPS Diagnostics Merge to Create Full Service Development Company

Lumos Diagnostics, a previous spinoff from Australia-based Planet Innovation, and RPS Diagnostics, a Florida-based commercial diagnostic developer, manufacturer, and marketer of POC diagnostic tests, announced today that they have merged.

Reach out to Lumos today to understand how we can deliver you a customized point-of-care diagnostic solution.